NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). 

The company's primary drug candidates are NRX-100 (IV ketamine) and NRX-101. NRX-100 is being developed for the treatment of suicidal depression. NRX-101, an FDA-designated investigational Breakthrough Therapy, is being developed for suicidal treatment-resistant bipolar depression and chronic pain. NRx has also expanded its focus to include the treatment of complicated urinary tract infections (cUTIs) and urosepsis. 

In February 2024, NRx incorporated HOPE Therapeutics, a subsidiary focused on delivering advanced psychiatric treatments, including ketamine-focused therapy for depression and suicidality. In August 2024, HOPE Therapeutics acquired interventional psychiatry clinics, including five operational clinics in the Western US for USD 30 million. With this acquisition, HOPE Therapeutics creates a unified network of clinics providing ketamine therapy and other treatments for suicidal depression, treatment-resistant depression, and PTSD. In October 2024, it acquired a leading West Coast interventional psychiatric clinic. And during the same month, it acquired interventional psychiatry clinics in Florida.

In 2023, NRx significantly reduced its corporate overhead by 50%. The company also reduced its net loss from USD 39.8 million in 2022 to USD 30.2 million in 2023, a 25% improvement during this period. 

The company is listed on the Nasdaq under the ticker symbol “NRXP.”

Key customers and partnerships

NRx Pharmaceuticals has partnered with Alvogen and Lotus for the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. It has also collaborated with Nephron Pharmaceuticals to develop a single-patient presentation of ketamine.